APC consultations

HNY APC and its subgroups hold open consultations on decisions which affect patient care. This may include updated formulary chapters, new or updated clinical guidelines or commissioning statements, or changes to formulary status. All comments received are carefully considered by the group which made the decision, before a final recommendation is made. Decisions are then reviewed by the HNY APC for information or approval, as appropriate.

Consultations typically run for four weeks, and comments are invited from all stakeholders across Humber and North Yorkshire. You can comment on current proposals via the links in the table below.

Title:	Information:	Feedback:	End Date:
NICE 30 day TAs – somapacitan, dapagliflozin, mirikizumab	We now seek comments on the implementation of three NICE technology appraisals with 30 day implementation periods: – somapacitan for growth hormone deficiency – dapagliflozin for CKD – mirikizumab for Crohn’s disease This consultation will run for two weeks and closes at 5pm on Wednesday 30th July	Feedback form	5pm on Wednesday 30th July
HNY Medicines, Formulary Group proposed actions from June 2025	On behalf of the HNY Medicines Formulary Group, we now seek comments on the actions proposed at the June 2025 meeting. This consultation will run for four weeks and closes at 5pm on Friday 8th August June	Feedback form	5pm on Friday 8th August
Guidelines for Pharmacological Management of Overactive Bladder (OAB) /Mixed Urinary Incontinence (UI) in Adult Women in Primary Care	Following the June meeting of HNY Medicines Formulary Group, we now seek comments on a draft overactive bladder (OAB) pathway. This consultation will run for four weeks and closes at 5pm on Friday 8th August June	Feedback form	5pm on Friday 8th August

Please direct any questions to the secretariat at nuth.hnyapc@nhs.net.